The Department of Health Care Services (DHCS) releases Drug Utilization Review (DUR) articles which provide timely and relevant information on drug-specific therapy issues.
On December 29, 2022, Congress Eliminated the Data-Waiver Program with the full support of the Drug Enforcement Agency (DEA). The goal was to make medication for opioid use disorder readily available for those in need.
The Data-Waiver registration requirement is no longer required to prescribe buprenorphine in order to treat patients with opioid use disorder. Prescribers now only require a standard DEA registration number and are no longer limited to a patient cap when treating for opioid use disorder with buprenorphine. Starting June 2023, all prescribers of controlled substances must undergo new training requirements.
Read the full Removal of DATA-Waiver Requirement article.